atamestane

Atamestane is a synthetic steroidal aromatase inhibitor developed as an antineoplastic agent. It acts by binding irreversibly and selectively to the enzyme aromatase (CYP19A1), thereby blocking the conversion of androgenic precursors into estrogens and reducing estrogen levels in the body. This mechanism makes it useful for hormone-dependent cancers such as breast cancer. Atamestane does not exhibit other intrinsic hormonal or antihormonal activities and does not inhibit other cytochrome P450-dependent enzymes involved in adrenal steroidogenesis. It was investigated primarily for advanced breast cancer and benign prostatic hyperplasia but was discontinued after clinical trials showed no efficacy advantage over existing therapies[1][2][3][4][5].

Other names

metandroden1-methylandrosta-1,4-diene-3,17-dione